All the news Showing 10 of 816 articles from: Health services, policy and advocacyGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Test-and-treat leads to sustained fall in hepatitis C in Swiss gay men with HIV Keith Alcorn / 18 April 2022 Intensive screening for hepatitis C, treatment and risk reduction counselling have led to sustained declines in hepatitis C prevalence and new cases of hepatitis C among gay and bisexual men living with ... Vaccine “Unaffordable” in Hepatitis B Endemic Liberia Front Page Africa / 09 March 2022 Decline in hepatitis C infections globally is encouraging but still not enough Center for Disease Analysis press release / 09 March 2022 Hepatitis C treatment and cure targets for people living with HIV still not being met in Europe Alain Volny-Anne / 22 February 2022 While over 90% of people living with HIV in Europe have been tested for hepatitis C, diagnosis remains suboptimal in the east of the continent. In three of five European ... The EASL–Lancet Liver Commission calls for a paradigm shift in the liver disease response in Europe EASL / 13 December 2021 Treatment for hepatitis B and C fell in 2020 due to COVID-19, global survey finds Keith Alcorn / 16 November 2021 Viral hepatitis tests and treatment declined significantly during 2020 as a consequence of the COVID-19 pandemic, a survey of 31 liver centres on five continents has shown. The decline in testing and ... Hepatitis C elimination: less than 25% of people with hepatitis C diagnosed globally Keith Alcorn / 15 November 2021 The global prevalence of hepatitis C has declined since 2015, partly due to scale-up of direct-acting antiviral treatment, but fewer than one in four people with hepatitis C has been diagnosed, ... Hepatitis C treatment in US declined from 2015 to 2020 Liz Highleyman / 14 November 2021 From a height of more than 164,000 in 2015, the number of people treated with direct-acting antiviral (DAA) therapy for hepatitis C has steadily declined, reaching a low point during the COVID-19 pandemic, ... Hepatitis C and Tuberculosis Long-Acting Medicines: Analysis of Patenting Trends and Implications for Access Treatment Action Group / 04 November 2021 Australia: Sustained investment is needed to eliminate hepatitis C by 2030 Burnet Institute / 04 November 2021 ← First12345...82Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Access to medicines & diagnostics Hepatitis C elimination Models of care Finance, funding & health economics National policy European policy International policy Activism and civil society Pharmaceutical industry Social issues Conference news Noticeboard Email bulletins News feeds